Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efgartigimod alfa-qvfc
- Development stage
- Approved
- Lead developer
- argenx
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Efgartigimod alfa-qvfc is the hyaluronidase component used in the fixed-dose subcutaneous combination product **efgartigimod alfa + hyaluronidase-qvfc**. It is a recombinant human hyaluronidase that transiently depolymerizes hyaluronan in the subcutaneous space, increasing tissue permeability and facilitating dispersion and absorption of coadministered efgartigimod alfa after subcutaneous injection. It is part of the marketed product VYVGART HYTRULO developed by argenx for autoimmune diseases including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, but efgartigimod alfa-qvfc itself is not the FcRn-binding therapeutic moiety and should be understood as the delivery-enabling enzyme component of the combination formulation.
- Other names
- efgartigimod alfa-qvfc
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on efgartigimod alfa-qvfc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efgartigimod alfa-qvfc.